Ovarian cancer in the older patient: where are we now? What to do next?

Authors:
Rousseau F; Ranchon F; Bardin C; Bakrin N; Lavoué V and 2 more

Journal:
Ther Adv Med Oncol

Publication Year: 2023

DOI:
10.1177/17588359231192397

PMCID:
PMC10505350

PMID:
37724138

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Ther Adv Med Oncol

Abbreviation: Ther Adv Med Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Oncology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-an…
Petrelli F; Antista M; Marra F and 8 more (2024) - Transparency Score: 3/6
A phase II study evaluating the efficacy of enzalutamide and the role of liquid biopsy for evaluati…
Sepe P; Procopio G; Pircher CC and 16 more (2024) - Transparency Score: 4/6
A prospective phase II single-arm study and predictive factor analysis of irinotecan as third-line …
Yu N; Huang S; Zhang Z and 9 more (2024) - Transparency Score: 4/6
Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer.
Bai Q; Shi X; Zhou X and 3 more (2024) - Transparency Score: 3/6
Chronological improvement of survival in patients with advanced gastric cancer over 15 years.
Ogata T; Narita Y; Oze I and 14 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"FR reported participation in a specialist advisory board for Bristol-Myers Squibb. LB reported personal fees from AstraZeneca, Clovis Oncology and GlaxoSmithKline. CF reported personal fees from Leo Pharma, Pfizer, MSD Oncology, Teva, AstraZeneca, Baxter, Eisai, Janssen Oncology, Novartis, Chugai Pharma and Astellas Pharma outside the submitted work; grants from Chugai Pharma, Pfizer, Pierre Fabre and Astellas Pharma outside the submit-ted work and non-financial support from Janssen Oncology, Pierre Fabre, AstraZeneca and Leo Pharma outside the submitted work. FR, CB, NB and VL declared no conflict of interest."

Evidence found in paper:

"Funding: The authors received no financial support for the research, authorship, and/or publication of this article."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025